Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention

Next Previous
Trial Profile

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceuticals; Pfizer

    • Most Recent Events

    • 27 Apr 2023 Results from a 52-week, open-label extension phase (n=603) assessing the safety and tolerability of rimegepant 75 mg dosed every other day (EOD) for the preventive treatment of migraine and as-needed (PRN) for acute treatment on nonscheduled dosing days, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 27 Apr 2023 Results assessing the effects of rimegepant 75 mg on monthly migraine days (MMDs) through 52 weeks of open-label treatment when dosed every other day (EOD) plus as-needed (PRN) on nonscheduled dosing days, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 27 Apr 2023 Results assessing the effects of rimegepant on quality of life over 1-year of open-label treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top